How Shilajit Talks to Bone Cells: What the Newest Lab Research Shows

What did the 2022 stem cell study find?

The study is Kangari and colleagues, published in 2022. The researchers took human adipose-derived stem cells, meaning stem cells harvested from fat tissue, and exposed them to shilajit at three concentrations.

Normally, pushing a stem cell to become a bone-building osteoblast requires osteogenic medium, a mix of lab-grade growth factors added on purpose. The researchers ran the experiment both with and without that medium.

Shilajit "showed osteoinductive property in the absence of OM," in the authors' own words. That means it started the differentiation process on its own, with none of the usual chemical push. With shilajit added, the stem cells raised their alkaline phosphatase activity and increased calcium deposition, the two lab markers that confirm bone-building cells are forming and getting to work.

Shilajit did what growth factors are normally needed to do. That single sentence is the receipt behind the phrase "shilajit turns stem cells into bone cells."

What happens to the cells that break bone down?

Bone is never built once and left alone. It is rebuilt in a constant cycle. Osteoblasts lay new bone down. Osteoclasts break old bone apart.

Two signaling molecules run that negotiation. RANKL tells osteoclasts to activate. OPG blocks that signal.

A 2020 study by Azizpour and colleagues tested mumie extract, a close relative of shilajit, directly on human MG63 bone cells. At 200 micrograms per milliliter, the extract significantly decreased RANKL expression and increased OPG expression, raising the OPG-to-RANKL ratio compared to untreated cells.

That is the cell-level version of a pattern already documented in real women. The 2022 Pingali trial found the same RANKL-down, OPG-up shift in the blood of postmenopausal women taking shilajit. Seeing the identical signal move in isolated human bone cells is what a mechanism behind a clinical result is supposed to look like.

A separate 2019 study by Abbasi and colleagues, using the same MG63 human osteoblast-like cells, found that low-dose mumie extract raised cell proliferation:

• 100 to 200 micrograms per milliliter increased proliferation of bone-building cells.
• The effect held across repeated measurements in the same cell line.
• Bone-building activity rose without any added growth factor.

Is there a safe dose in these lab studies?

Every finding above comes with a limit, and the honest one is a dose ceiling. In the Abbasi study, 300 micrograms per milliliter of mumie extract reversed the benefit and became cytotoxic to the cells.

That is a lab-dish concentration, not a supplement serving size, and the two units are not interchangeable. What it tells researchers is that more is not simply better at the cellular level, which is a normal finding in pharmacology and one that belongs in this summary rather than left out.

Does the same signal show up in animals?

Cell-dish findings only mean so much until they show up in a living body. A 2025 study by Santos and colleagues gave humic acid, one of shilajit's key constituent compounds, to mice in a menopause model by daily gavage for 28 days.

The treated mice showed a real physical result in their femurs:

• Calcium levels in the femur rose.
• The calcium-to-phosphorus ratio, a marker of bone mineral quality, improved.
• Hydrogen peroxide, a marker of oxidative stress, fell in both the liver and kidney.

A menopause-model animal is not a menopausal woman, and gavage dosing in mice does not translate directly into a human capsule dose. What the study adds is a second, independent line of evidence, in a living animal rather than a dish, pointing the same direction as the cell studies above.

How does this connect to the human bone trial?

This blog has already covered the human side of shilajit's bone research. A 48-week, randomized, placebo-controlled trial by Pingali and colleagues found that every single woman in the treatment group reversed her osteoporosis in 6 months. That is the clinical result. This article is about the mechanism underneath it.

Two different scientific tools, aimed at the same question, are landing on the same answer. That agreement is what makes a mechanism explanation credible rather than convenient.

What these lab studies can't tell you

None of the cell and animal work above is a substitute for the clinical trial, and it should not be read as one. A few honest limits:

• Cell-dish concentrations do not convert directly into a milligram supplement dose. The units are not the same, and nobody has published that conversion for shilajit.
• Cytotoxicity at higher lab doses is a real finding, and it argues for staying within a studied range rather than assuming unlimited amounts help more.
• Mouse gavage studies measure femur calcium and oxidative markers, not a full skeleton or a fracture outcome.
• The mechanism work explains why the human result might be happening. It does not replace the human result as the evidence that matters most.

Optimum Shilajit

If you want to see the sourcing and testing behind the shilajit used in this research summary, has the full ingredient breakdown.

See Optimum Shilajit